<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117556</url>
  </required_header>
  <id_info>
    <org_study_id>17.0315</org_study_id>
    <nct_id>NCT03117556</nct_id>
  </id_info>
  <brief_title>Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer</brief_title>
  <official_title>Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norton Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the efficacy of bilateral thoracoscopic splanchnicectomy (BTS) to
      conventional narcotic analgesia for control of abdominal pain in patients with pancreatic
      ductal adenocarcinoma not amenable to surgical resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with unresectable pancreatic cancer will be considered for participation in this
      study. Patients with locally advanced or metastatic cancer that meet inclusion criteria will
      be randomized into one of two arms, treatment with BTS and narcotic analgesia or treatment
      with narcotic analgesia alone. After randomization a baseline pain score will be assessed
      using the visual analog pain scale. Narcotic dosage and frequency will be evaluated at the
      time of enrollment. A pre-treatment quality of life score will be recorded using the SF-12®
      Patient Questionnaire. Patients will also be queried about the presence of nausea and reflux.

      After all baseline assessments are complete patients will be taken to the OR to undergo their
      assigned procedure. BTS and infusaport placement will be performed on patients randomly
      selected for treatment with BTS and narcotic analgesia. BTS will be performed as described in
      the study procedure. Patients chosen to be treated with narcotic analgesia alone will undergo
      infusaport placement only. An evaluation will be completed postoperatively in which the
      length of stay, post-op complications, and chest X-ray results will be recorded. Follow-up
      assessments will be conducted 24-48 hours post-procedure and at the time of discharge.
      Further follow-up assessments will be conducted 14 days, 30 days, and 90 days post-procedure
      during an office visit with the clinical research team or medical oncology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All patients with unresectable pancreatic cancer will be considered for participation in this study. Patients with locally advanced or metastatic cancer that meet inclusion criteria will be randomized into one of two arms, treatment with BTS and narcotic analgesia or treatment with narcotic analgesia alone.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal pain</measure>
    <time_frame>1 year</time_frame>
    <description>Pain will be measured using a visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Narcotic Requirements</measure>
    <time_frame>1 year</time_frame>
    <description>Narcotic usage will be monitored at each follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of Life will be measured using the SF-12® Patient Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Nausea</measure>
    <time_frame>1 year</time_frame>
    <description>Patients will be queried about the presence of nausea using a questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Reflux</measure>
    <time_frame>1 Year</time_frame>
    <description>Patients will be queried about the presence of reflux using a questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Anti-emetics</measure>
    <time_frame>1 year</time_frame>
    <description>anti-emetic dosage will be measures at each follow-up visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Unresectable Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>BTS Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No BTS Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral Thoracoscopic Splanchnicectomy</intervention_name>
    <description>BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.</description>
    <arm_group_label>BTS Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be 18 years of age

          2. Diagnosed with stage III/IV pancreatic cancer

          3. Willing and able to comply with the protocol requirements

          4. Able to comprehend and have signed the Informed Consent Form (ICF) to participate in
             the study

        Exclusion Criteria:

          1. Participating in another clinical trial for the treatment of cancer at the time of
             screening

          2. Pregnant or currently breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gary C Vitale, MD</last_name>
    <phone>(502) 629-2278</phone>
    <email>gcvita01@louisville.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neal Bhutiani, MD</last_name>
    <phone>(502) 629-6950</phone>
    <email>neal.bhutiani@louisville.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary C Vitale, MD</last_name>
      <phone>502-629-2278</phone>
      <email>gcvita01@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amber N Brown, BA</last_name>
      <phone>502-216-3264</phone>
      <email>anbrow14@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gary C Vitale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Tierney, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wesley Jones, MD</last_name>
      <phone>864-884-0932</phone>
      <email>wjones@ghs.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013 Jun;144(6):1252-61. doi: 10.1053/j.gastro.2013.01.068. Review.</citation>
    <PMID>23622135</PMID>
  </reference>
  <reference>
    <citation>Gachago C, Draganov PV. Pain management in chronic pancreatitis. World J Gastroenterol. 2008 May 28;14(20):3137-48. Review.</citation>
    <PMID>18506917</PMID>
  </reference>
  <reference>
    <citation>Katri KM, Ramadan BA, Mohamed FS. Thoracoscopic splanchnicectomy for pain control in irresectable pancreatic cancer. J Laparoendosc Adv Surg Tech A. 2008 Apr;18(2):199-203. doi: 10.1089/lap.2007.0066.</citation>
    <PMID>18373443</PMID>
  </reference>
  <reference>
    <citation>Jones WB, Jordan P, Pudi M. Pain management of pancreatic head adenocarcinomas that are unresectable: celiac plexus neurolysis and splanchnicectomy. J Gastrointest Oncol. 2015 Aug;6(4):445-51. doi: 10.3978/j.issn.2078-6891.2015.052. Review.</citation>
    <PMID>26261731</PMID>
  </reference>
  <reference>
    <citation>Malec-Milewska MB, Tarnowski W, Ciesielski AE, Michalik E, Guc MR, Jastrzebski JA. Prospective evaluation of pain control and quality of life in patients with chronic pancreatitis following bilateral thoracoscopic splanchnicectomy. Surg Endosc. 2013 Oct;27(10):3639-45. doi: 10.1007/s00464-013-2937-0. Epub 2013 Apr 10.</citation>
    <PMID>23572221</PMID>
  </reference>
  <reference>
    <citation>Davis BR, Vitale M, Lecompte M, Vitale D, Vitale GC. An objective study of pain relief in chronic pancreatitis from bilateral thoracoscopic splanchnicectomy. Am Surg. 2008 Jun;74(6):510-4; discussion 514-5.</citation>
    <PMID>18556993</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Gary C. Vitale, MD</investigator_full_name>
    <investigator_title>Professor of medicine, General Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

